Huisheng Biopharmaceutical Co., Ltd

Huisheng Biopharmaceutical Co Ltd Innovating Diabetes Care for a Healthier Future --About Us-- Huisheng Biopharmaceutical, headquartered in Jilin, China, is a pioneering company de

dicated to the research, development, and manufacturing of high-quality insulin formulations and comprehensive diabetes treatments. With strong R&D capabilities, advanced production facilities, and a commitment to innovation, Huisheng is shaping the future of diabetes care by offering reliable, affordable, and globally accessible solutions. --Our Achievements-- Huisheng is proud to be the first company worldwide to successfully develop biosimilar versions of: *Insulin Degludec *Insulin Degludec & Aspart (70/30) Combination with high demanded traditional insulin products: *Insulin Aspart Injection *Insulin Aspart 30 Injection *Insulin Aspart 50 Injection These milestones demonstrate our industry leadership in insulin innovation and our ability to rapidly bring advanced therapies to market. --Comprehensive Diabetes Portfolio-- Huisheng provides a full spectrum of diabetes care solutions, including: Insulin formulations: Long-acting, rapid-acting, and premixed biosimilars Oral anti-diabetic medicines: Covering key small-molecule therapies and Next-generation GLP-1 therapies. Our integrated product pipeline enables us to support holistic diabetes management, from early intervention to long-term disease control. --Global Expansion-- Huisheng is actively expanding into international markets, with a special focus on Latin America, Asia, and the Middle East. We are building long-term partnerships through: *License-out *Finished product/API supply *Technology transfer collaborations Our mission is to ensure patients worldwide gain access to affordable, effective, and innovative diabetes therapies.